Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer

von Bian, Li, Xu, Feng-Rui, Jiang, Ze-Fei
Veröffentlicht in Chin Med J (Engl) (2020)

PTEN mutation, methylation and expression in breast cancer patients

von ZHANG, HONG-YAN, LIANG, FENG, JIA, ZHI-LING, SONG, SAN-TAI, JIANG, ZE-FEI
Veröffentlicht 2013

Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer

von Ye, Qing, Qi, Fan, Bian, Li, Zhang, Shao-Hua, Wang, Tao, Jiang, Ze-Fei
Veröffentlicht in Chin Med J (Engl) (2017)

Receptor conversion in metastatic breast cancer: a prognosticator of survival

von Meng, Xiangying, Song, Santai, Jiang, Ze-Fei, Sun, Bing, Wang, Tao, Zhang, Shaohua, Wu, Shikai
Veröffentlicht in Oncotarget (2016)

Evaluation of treatment response for breast cancer: are we entering the era of “biological complete remission”?

von Bian, Li, Wang, Tao, Liu, Yi, Zhang, Hui-Qiang, Song, Jin-Jie, Zhang, Shao-Hua, Wu, Shi-Kai, Song, San-Tai, Jiang, Ze-Fei
Veröffentlicht 2012

Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab

von Bian, Li, Wang, Tao, Zhang, Shao-hua, Zhang, Hui-qiang, Guo, Yun-fei, Du, Ge, Li, Wang, Wu, Shi-kai, Song, San-tai, Jiang, Ze-fei
Veröffentlicht 2014

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial

von Li, Jian-wei, Liu, Guang-yu, Ji, Ya-jie, Yan, Xia, Pang, Da, Jiang, Ze-fei, Chen, De-dian, Zhang, Bin, Xu, Bing-he, Shao, Zhi-ming
Veröffentlicht in Cancer Manag Res (2018)

Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma

von Li, Yue-Min, Song, San-Tai, Jiang, Ze-Fei, Zhang, Qi, Su, Chang-Qing, Liao, Guo-Qing, Qu, Yi-Mei, Xie, Guo-Qing, Li, Ming-Ying, Ge, Fei-Jiao, Qian, Qi-Jun
Veröffentlicht 2008

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients

von Xu, Bing-He, Jiang, Ze-Fei, Chua, Daniel, Shao, Zhi-Min, Luo, Rong-Cheng, Wang, Xiao-Jia, Liu, Dong-Geng, Yeo, Winnie, Yu, Shi-Ying, Newstat, Beth, Preston, Alka, Martin, Anne-Marie, Chi, Hai-Dong, Wang, Li
Veröffentlicht 2011

Guidelines on the diagnosis and treatment of breast cancer (2011 edition)

von Zhang, Bao-Ning, Cao, Xu-Chen, Chen, Jia-Yi, Chen, Jie, Fu, Li, Hu, Xi-Chun, Jiang, Ze-Fei, Li, Hong-Yuan, Liao, Ning, Liu, Dong-Geng, Tao, Ouyang, Shao, Zhi-Min, Sun, Qiang, Wang, Shui, Wang, Yong-Sheng, Xu, Bing-He, Zhang, Jin
Veröffentlicht 2012

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study

von Zhang, Qing Yuan, Sun, Tao, Yin, Yong Mei, Li, Hui Ping, Yan, Min, Tong, Zhong Sheng, Oppermann, Christina P., Liu, Yun Peng, Costa, Romulo, Li, Man, Cheng, Ying, Ouyang, Qu Chang, Chen, Xi, Liao, Ning, Wu, Xin Hong, Wang, Xiao Jia, Feng, Ji Feng, Hegg, Roberto, Kanakasetty, G.B., Coccia-Portugal, Maria A., Han, Ru Bing, Lu, Yi, Chi, Hai Dong, Jiang, Ze Fei, Hu, Xi Chun
Veröffentlicht in Ther Adv Med Oncol (2020)